Labcorp launched two assays—Plasma Detect ID and Plasma Detect Genome—expanding its molecular residual disease (MRD) testing suite nationwide. The personalized whole‑exome sequencing‑guided Plasma Detect ID targets stage I–III breast cancer and stage I–IIIA NSCLC, while Plasma Detect Genome is a whole‑genome MRD test for stage III colon cancer. Labcorp reported limits of detection down to 0.005 percent circulating tumor DNA, positioning the assays for sensitive post‑treatment surveillance. The company cited ongoing clinical studies and peer‑reviewed evidence demonstrating the tests’ utility in tracking early progression, predicting outcomes and identifying residual disease in diverse tumor types. Labcorp emphasized scalability and integration into clinical workflows as central to commercialization. Commercial rollout aims to support personalized surveillance strategies and could pressure payors and guideline committees to define MRD use cases. Adoption will hinge on prospective clinical‑utility data and reimbursement pathways.